Table 2.
Symptom score and symptom score change at three time points compared with baseline for women completing at least 6 months of medication, subdivided per dose arm.
| Characteristics | Month 0 | Month 3 | Month 6 | Month 9 |
|---|---|---|---|---|
| All women | ||||
| Number of women reporting side effects | 32 | 31 | 29 | 30 |
| Symptom scorea, mean (95% CIb) | 67.9 (65.5-70.4) | 68.9 (66.1-71.6) | 66.2 (63.0-69.4) | 69.8 (66.7-73.0) |
| Absolute difference in symptom scorec, mean (95% CIb) | Ref. | 1.1 (−1.6-3.8) | −1.4 (−4.4 to 1.5) | 2.6 (0.6-4.6) |
| Women in the 10 mg arm | ||||
| Number of women reporting side effects | 18 | 17 | 17 | 18 |
| Symptom scorea, mean (95% CIb) | 66.2 (63.0-69.4) | 66.3 (62.8-69.8) | 64.3 (60.2-68.4) | 67.4 (63.5-71.3) |
| Absolute difference in symptom scorec, mean (95% CIb) | Ref. | 0.4 (−3.3 to 4.1) | −1.6 (−5.5 to 2.4) | 1.8 (−0.8 to 4.5) |
| Women in the 20 mg arm | ||||
| Number of women reporting side effects | 14 | 14 | 12 | 12 |
| Symptom score1, mean (95% CI2) | 70.1 (66.5-73.7) | 72.0 (68.1-75.8) | 68.9 (64.0-73.7) | 73.4 (68.7-78.2) |
| Absolute difference in symptom score3, mean (95% CI2) | Ref. | 1.8 (−2.1-5.8) | −1.3 (−5.9 to 3.4) | 3.7 (0.5-6.8) |
Higher symptom score means less symptoms.
95% confidence intervals.
Higher absolute difference means less symptoms.